|Bid||3.1200 x 900|
|Ask||0.0000 x 1000|
|Day's Range||3.1500 - 3.2200|
|52 Week Range||0.4000 - 6.8900|
|Beta (5Y Monthly)||2.44|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the first quarter ended March 31, 2020 and provided an update on recent operating developments, including the status of the previously announced LOIs with Canndoc Ltd, a wholly owned subsidiary of publicly-traded Intercure Ltd. (TASE: INCR).
Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that it has signed a development agreement with an international consortium to examine the therapeutic effects of ApoGraft treated stem cells on the reduction of pulmonary manifestations caused by COVID-19. The Company has completed the technology and material transfer and the pre-clinical studies are progressing. The development agreement includes a commercial component, enabling the Company to receive royalties upon the commercialization of the intended product. The Company did not disclose the terms of the agreement, nor any members of the international consortium.